Segall Bryant & Hamill LLC grew its holdings in shares of QuidelOrtho Corporation (NASDAQ:QDEL – Free Report) by 29.2% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,543,410 shares of the company’s stock after purchasing an additional 348,549 shares during the period. Segall Bryant & Hamill LLC’s holdings in QuidelOrtho were worth $25,358,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Global Retirement Partners LLC increased its stake in QuidelOrtho by 3,691.7% during the 4th quarter. Global Retirement Partners LLC now owns 910 shares of the company’s stock valued at $26,000 after buying an additional 886 shares during the period. Camelot Portfolios LLC bought a new stake in shares of QuidelOrtho during the 4th quarter worth about $29,000. Hantz Financial Services Inc. lifted its stake in shares of QuidelOrtho by 50.3% in the 4th quarter. Hantz Financial Services Inc. now owns 1,082 shares of the company’s stock worth $31,000 after acquiring an additional 362 shares during the period. Larson Financial Group LLC boosted its holdings in shares of QuidelOrtho by 322.2% in the third quarter. Larson Financial Group LLC now owns 1,330 shares of the company’s stock valued at $39,000 after acquiring an additional 1,015 shares in the last quarter. Finally, Leonteq Securities AG boosted its holdings in shares of QuidelOrtho by 555.2% in the first quarter. Leonteq Securities AG now owns 3,466 shares of the company’s stock valued at $57,000 after acquiring an additional 2,937 shares in the last quarter. 99.00% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
Several equities research analysts recently commented on the company. Zacks Research raised QuidelOrtho from a “strong sell” rating to a “hold” rating in a report on Monday, June 15th. Citigroup increased their price target on QuidelOrtho from $13.00 to $18.00 and gave the company a “neutral” rating in a research note on Wednesday, July 8th. UBS Group reiterated a “neutral” rating and set a $12.00 price target on shares of QuidelOrtho in a research report on Thursday, May 7th. JPMorgan Chase & Co. boosted their price objective on QuidelOrtho from $11.00 to $12.00 and gave the stock an “underweight” rating in a research note on Wednesday, July 1st. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of QuidelOrtho in a report on Friday, July 17th. Four investment analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Reduce” and an average price target of $13.62.
QuidelOrtho Price Performance
Shares of NASDAQ:QDEL opened at $16.77 on Friday. QuidelOrtho Corporation has a one year low of $9.92 and a one year high of $35.58. The stock has a fifty day moving average of $15.37 and a 200-day moving average of $18.16. The company has a market capitalization of $1.14 billion, a PE ratio of -0.94 and a beta of 0.69. The company has a debt-to-equity ratio of 1.33, a quick ratio of 0.80 and a current ratio of 1.43.
QuidelOrtho (NASDAQ:QDEL – Get Free Report) last issued its earnings results on Tuesday, May 5th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.41). The company had revenue of $619.80 million during the quarter, compared to analyst estimates of $665.23 million. QuidelOrtho had a positive return on equity of 4.25% and a negative net margin of 45.57%.The business’s revenue was down 10.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.74 earnings per share. QuidelOrtho has set its FY 2026 guidance at 1.800-2.000 EPS. As a group, equities analysts anticipate that QuidelOrtho Corporation will post 1.87 EPS for the current fiscal year.
QuidelOrtho Company Profile
QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.
The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.
Read More
- Five stocks we like better than QuidelOrtho
- Chevron’s Strong Quarter Shows Why It Still Leads the Energy Sector
- Amazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull Case
- Apple’s Record Quarter Could Not Outrun Its Guidance Problem
- McKesson’s Compounding Keeps Adding Up
Want to see what other hedge funds are holding QDEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for QuidelOrtho Corporation (NASDAQ:QDEL – Free Report).
Receive News & Ratings for QuidelOrtho Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for QuidelOrtho and related companies with MarketBeat.com's FREE daily email newsletter.
